Analysts think INDP stock price could increase by 2866%
Aug 09, 2025, 11:25 AM
-41.39%
What does INDP do
Indaptus Therapeutics, a preclinical biotechnology company based in New York City, focuses on multi-targeted immune system activation using a Decoy platform for anti-tumor and anti-viral responses. Its lead candidate, Decoy20, shows promise against chronic HBV and HIV infections.
4 analysts think INDP stock price will increase by 2866.17%. The current median analyst target is $199.92 compared to a current stock price of $6.74. The lowest analysts target is $56.56 and the highest analyst target is $352.80.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
